Complex correction of metabolic changes and endothelial dysfunction in patients with ischemic heart disease and eff ort angina of functional class II

Objective: to study the role of free radical processes, disturbances in nitric oxide homeostasis and cholesterol metabolism in the formation of endothelial disorders in patients with chronic heart disease (CHD) with eff ort angina pectoris functional class II (FC); to substantiate the complex correction of disorders. 
Material and methods. The study included 75 patients with coronary artery disease and eff ort angina FC II at the age of 50.1 ± 10 years old in the course of a year. The patients were divided into 4 groups: 1st group — control, 2nd group — data obtained on the background of basic therapy; 3rd group — basic therapy + atorvastatin; 4th group — a combination of basic therapy with atorvastatin and coenzyme Q₁₀. In all patients, the intensity of lipid peroxidation, the activity of the antioxidant system, the content of NO metabolites and cholesterol metabolism were determined. To assess the functional state of the heart, an ECG study, daily ECG monitoring with the use of the Microvit MT-101 Holter system and blood pressure were performed. 
Results. The data showed the development of oxidative stress, inhibition of AOD cells and a decrease in the NO metabolites content and impairment of its bioavailability due to atherogenic changes in the vascular wall. Metabolic changes were accompanied by hypertension, ECG changes and anginal attacks. Combined therapy with atorvastatin and coenzyme Q₁₀ against the background of basic therapy caused a positive dynamics of metabolic and functional disorders. 
Conclusion. The results of complex therapy with an inhibitor of HMG-CoA reductase and coenzyme Q₁₀ proved the effi cacy of the infl uence on oxidation-reduction reactions, endothelial function, total cholesterol, LDL cholesterol, HDL cholesterol and functional parameters of the heart.

1. Mach F., Baigent C., Catapano A.L, Koskinas K.C., Casula M., Ba di mon L. et al. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modifi cation to reduce cardiovascular risk. Rossijskij zhurnal kardiologii. 2020;25(5):3826. (in Russian). DOI:10.15829/1560-4071-2020-3826

2. Borеn J., Williams K.J. The central role of arterial retention of cho lesterol-rich apolipoprotein-B-containing lipoproteins in the patho genesis of atherosclerosis: a triumph of simplicity. Current Opinion in Lipidology. 2016;27(5):473–483. DOI:10.1097/MOL.0000000000000330

3. Asakawa T., Matsushita S. Coloring conditions of thiobarbituricacid test, for detecting lipid hidroperoxides. Lipids. 1980;15(5):137–40,. DOI:10.1007/BF02540959

4. Sirota T.V. A new approach in the study of adrenaline autooxidation and its use to measure the activity of superoxide dismutase. Voprosy meditsinskoy khimii. 1999;3:263–272. (in Russian). [Electronic resource]. URL: https://www.elibrary.ru/item.asp?id=22513847

5. Korolyuk M.A., Ivanova L.I., Mayorova I.G. Method for determining the activity of catalase. Laboratornoe delo. 1988;1:16–19. (in Russian). [Electronic resource]. URL: https://www.elibrary.ru/item.asp?id=21757139

6. Kamyshnikov V.S. Determination of the content of ceruloplasmin activity. Spravochnik po klinikobiokhimicheskim issledovaniyam i laboratornoy diagnostike. 3-e izd. Moscow: MEDpress-inform, 2009:889. (in Russian). [Electronic resource]. URL: https://search.rsl.ru/ru/record/01004246961

7. Metel’skaya A.V., Gumanova N.G. Screening method for determination of serum nitric oxide metabolites. Klinicheskaya laboratornaya medicina. 2005;6:15–18. (in Russian). [Electronic resource]. URL: https://www.elibrary.ru/item.asp?id=17049510

8. Bovtyushko P.V., Grishaev S.L., Filippov E.A., Obrezan A.G. Markers of subclinical atherosclerosis in assessing the ten-year risk of cardiovascular events Kardio-Somatika. 2015;6(4):12–16. (in Russian). [Electronic resource]. URL: https://omnidoctor.ru/library/izdaniya-dlya-vrachey/cardiosomatika-kardiosomatika/cs2015/cs2015_4/markery-subklinicheskogo-ateroskleroza-v-otsenkedesyatiletnego-riska-razvitiya-serdechno-sosudistykh

9. Matusevich S.Yu., Karuzin K.A. Oxidative stress and its role in the formation of dysadaptation and pathology. Bioradikaly i antioksidanty. 2015;2(2):15–18. (in Russian). [Electronic resource]. URL: https://www.elibrary.ru/item.asp?id=25051857

10. Lankin V.Z., Tikhaze A.K., Konovalova G.G. The eff ect of lipid-lowering therapy on the level of oxidatively modifi ed low-density lipoproteins. Rossiyskiy kardiologicheskiy zhurnal. 2018;23(8):39–44. (in Russian). DOI:10.15829/1560-4071-2018-8-39-44

11. Lipovetskiy B.M. Dyslipidemias, atherosclerosis and their relationship with ischemic heart and brain disease. St. Petersburg: Eco-Vector, 2012:79. (in Russian). [Electronic resource]. URL: https://search.rsl.ru/ru/record/01006539578

12. Tikhomirova Yu.R., Kontorshchikova K.N. Indicators of lipid metabolism and oxidative modifi cation of proteins in metabolic disorders. Bioradikaly i antioksidanty. 2015;2(1):62–66. (in Russian). [Electronic resource]. URL: https://www.elibrary.ru/item.asp?id=23478164

13. Sizova Zh.M., Zakharova V.L., Alibeyli K.A. Possibilities of coenzyme Q10 in the complex therapy of patients with chronic heart failure and its impact on quality of life indicators. Meditsinskiy Sovet. 2019;5:90–95. (in Russian). DOI:10.21518/2079-701X-2019-5-90-95

14. Ezhov M.V., Sergienko I.V., Aronov D.M., Arabidze G.G., Ahmedzhanov N.M., Bazhan S.S., Balahonova T.V. et al. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations VI revision. Ateroskleroz i dislipidemii. 2017;3(28):5–22. (in Russian). [Electronic resource]. URL: https://www.elibrary.ru/item.asp?id=29667695

15. Suhorukov V.N., Karagodin V.P., Orekhov A.N. Atherogenic modifi cations of low density lipoproteins. Biomedicinskaya himiya. 2016;62(4):391–402. (in Russian). DOI: 10.18097/PBMC20166204391